Completed PHASE2 INTERVENTIONAL 1-arm NCT03012594

Lanreotide in the Treatment of Small Bowel Motility Disorders

A Pilot Study to Evaluate Safety and Effectiveness of Lanreotide in the Treatment of Patients With Small Bowel Motility Disorders (SBMD): a Prospective, Non-randomized, Single-center Study of 20 Participants

Sponsor: Ipsen

Conditions Gastrointestinal Motility Disorder Intestinal Disease

Interventions Lanreotide

Updated 10 times since 2017 Last updated: Dec 23, 2020 Started: May 11, 2017 Primary completion: Oct 21, 2018 Completion: Mar 11, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Gastrointestinal Motility Disorder and Intestinal Disease and is currently completed. Ipsen leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Feb 2021 — Dec 2021 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2
Mar 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ipsen
Northwell Health

Data source: Northwell Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Hyde Park, United States
• New York, United States